Andrew von Eschenbach, M.D., Former FDA Commissioner and Leading Prostate Cancer Expert, Elected to Viamet Pharmaceuticals Board of Directors
1/19/2011 7:59:50 AM
MORRISVILLE, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., which discovers and develops best-in-class inhibitors of key metalloenzymes, announced today that Andrew von Eschenbach, M.D., former U.S. Food and Drug Administration (FDA) Commissioner and former Director of the U.S. National Cancer Institute (NCI), has joined the company’s Board of Directors. Dr. von Eschenbach is a recognized leader in urology, prostate cancer research, patient healthcare policy and pharmaceutical regulation.
comments powered by